4basebio inks supply deal with Italy's Neomatrix

The AIM-traded firm said the agreement aimed to develop a personalised cancer therapy using its proprietary ‘hpDNA’.

As part of the agreement, 4basebio would supply clinical and preclinical DNA materials for Neomatrix's neoantigen cancer vaccine programme.

The programme was scheduled to begin enrolling patients early next year.

Neomatrix would have access to 4basebio's DNA products, including hpDNA and ‘oeDNA’.

The key component in Neomatrix's immunotherapy cancer treatment would be the personalised, clinical-grade DNA products, which would be manufactured and supplied by 4basebio.

“We are delighted to be working with Neomatrix in the delivery of neoantigen cancer vaccines,” said chief executive and chief scientific officer, Dr Heikki Lanckriet.

“4basebio’s DNA products offer significant advantages both in terms of performance and the time required to manufacture a personalised vaccine, which is particularly relevant where needle to needle time is paramount to clinical outcome.”

At 0803 BST, shares in 4basebio were up 1.35% at 562.5p.

Reporting by Josh White for Sharecast.com.